rosiglitazone has been researched along with Cancer of Mouth in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horn, TL; Johnson, WD; Lubet, RA; McCormick, DL; Peng, X; Steele, VE | 1 |
| Guo, XL; Lu, YY; Wang, HY; Wang, WF; Xin, M; Zhang, Y; Zhou, Y | 1 |
2 other study(ies) available for rosiglitazone and Cancer of Mouth
| Article | Year |
|---|---|
Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ.
Topics: 4-Nitroquinoline-1-oxide; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Male; Mouth Neoplasms; Pioglitazone; PPAR gamma; Quinolones; Rats; Rats, Inbred F344; Rosiglitazone; Thiazolidinediones | 2015 |
Rosiglitazone elevates sensitization of drug-resistant oral epidermoid carcinoma cells to vincristine by G2/M-phase arrest, independent of PPAR-γ pathway.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Survival; Cyclin B1; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Human Umbilical Vein Endothelial Cells; Humans; Inhibitory Concentration 50; M Phase Cell Cycle Checkpoints; Mouth Neoplasms; Neovascularization, Physiologic; Phosphatidylinositol 3-Kinases; Poly(ADP-ribose) Polymerases; Polymerization; PPAR gamma; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Rosiglitazone; Signal Transduction; Thiazolidinediones; Tubulin; Vincristine | 2016 |